NUMA1 and breast cancer: Six urinary diagnostic assays for BC have been approved for clinical use by the FDA: qualitative bladder tumor antigen (BTA) (BTA stat), quantitative BTA (BTA TRAK), quantitative nuclear matrix protein 22 (NMP22) (Alere NMP22), qualitative NMP22 (BladderCheck), fluorescent immunohistochemistry (ImmunoCyt), and fluorescence in situ hybridization (FISH) (UroVysion) [72,73,74,75].